Mayne Pharma Group Limited (ASX:MYX) has issued updates ahead of its Annual General Meeting scheduled for 10am Melbourne time on Friday, 20 November 2026, disclosing a delay by director nominee Dr Brett Wells in consenting to background checks, as well as corrections to proxy appointment provisions and clarifications to the proxy form.

Key Points

  • Dr Brett Wells provided consent for background checks only at 12.52am on Sunday, 15 November 2026, after multiple requests from Mayne Pharma since his nomination.
  • The company said it may not have sufficient time to complete background checks and determine whether material information should be disclosed to shareholders before proxies are lodged or votes cast on Dr Wells' election.
  • A correction has been issued to the proxy appointment provisions in the Notice of Meeting, replacing the original paragraph regarding shareholders who appoint two proxies.
  • The company clarified that the reference to "available proxies" on the proxy form relates to the Chair's voting intention with respect to undirected proxies only.

Resolution 4 – Dr Brett Wells Director Nomination Delay

Mayne Pharma disclosed that Dr Brett Wells, nominated for election as a director of the company, was asked on multiple occasions to consent to customary background checks recommended by the ASX Corporate Governance Council. Dr Wells provided his consent at 12.52am on Sunday, 15 November 2026. The company stated that as a result of this delay, it may not have sufficient time to complete those checks and determine whether anything material about Dr Wells' background should be disclosed to shareholders prior to proxy lodgement or the vote on his election at the AGM, scheduled for 20 November 2026.

Correction to Proxy Appointment Provisions in Notice of Meeting

The company disclosed a correction to paragraph 2 under the heading "Proxies and Shareholder Information" on page 6 of the Notice of Meeting, which was originally dispatched on 19 October 2026. The replacement text states that if a shareholder is entitled to cast two or more votes, they may appoint two proxies but no more, and may specify the proportion or number of votes each proxy is appointed to exercise. If no proportion or number is specified, each proxy may exercise half of the votes with fractions disregarded. If two proxies are appointed, neither proxy may vote on a show of hands.

Clarification of Proxy Form Voting Intention Statement

Mayne Pharma also provided a clarification regarding the shaded note on the proxy form under the heading "Step 2 Items of Business." The note states that if the Chair of the Meeting is appointed as proxy, the Chair intends to vote available proxies in the manner set out beside each resolution, reflecting the Board's recommendation. The company clarified that the reference to "available proxies" in that statement refers specifically to the Chair's voting intention with respect to undirected proxies. The filing further noted that the shaded "For" and "Against" statements beside each resolution represent the Board's recommendations, while shareholders retain the option to vote "For," "Against," or "Abstain."